Letter to Utah Congressional Delegation RE: H.R. 3, The Lower Drug Costs Now Act
May 25, 2021
Today, BioUtah, in conjunction with Centro Civico Mexicano, First Step House, International Cancer Advocacy Network, Mental Healthy FIT, Northern Utah Coalition, and Patel Family Investments, sent a letter to Utah’s congressional delegation expressing concern with the reintroduction of H.R. 3, The Lower Drug Costs Now Act. In the letter, the coalition states its concern about the bill’s negative impact on investment in drug discovery.
You may read the letter in its entirety here.
Recent News
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
- Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial